214 related articles for article (PubMed ID: 36264895)
1. Duchenne muscular dystrophy: RANK/RANKL/OPG (receptor activator of nuclear factor-kB/RANK ligand/osteoprotegerin) system and glucocorticoids.
Atilano-Miguel S; Barbosa-Cortés L; Ortiz-Muñiz R
Bol Med Hosp Infant Mex; 2022; 79(5):275-283. PubMed ID: 36264895
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular Dystrophy.
Boulanger Piette A; Hamoudi D; Marcadet L; Morin F; Argaw A; Ward L; Frenette J
Curr Osteoporos Rep; 2018 Oct; 16(5):541-553. PubMed ID: 30225627
[TBL] [Abstract][Full Text] [Related]
3. Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy.
Dufresne SS; Boulanger-Piette A; Bossé S; Argaw A; Hamoudi D; Marcadet L; Gamu D; Fajardo VA; Yagita H; Penninger JM; Russell Tupling A; Frenette J
Acta Neuropathol Commun; 2018 Apr; 6(1):31. PubMed ID: 29699580
[TBL] [Abstract][Full Text] [Related]
4. Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts.
Armada L; Marotta Pdos S; Pires FR; Siqueira JF
J Endod; 2015 Aug; 41(8):1281-7. PubMed ID: 25956608
[TBL] [Abstract][Full Text] [Related]
5. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
Liu W; Zhang X
Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
[TBL] [Abstract][Full Text] [Related]
6. Evaluating RANKL and OPG levels in patients with Duchenne muscular dystrophy.
Akhtar Ali S; Kang H; Olney R; Ramos-Platt L; Ryabets-Lienhard A; Cheung C; Georgia S; Pitukcheewanont P
Osteoporos Int; 2019 Nov; 30(11):2283-2288. PubMed ID: 31392399
[TBL] [Abstract][Full Text] [Related]
7. Expression of the RANK/RANKL/OPG system in the human intervertebral disc: implication for the pathogenesis of intervertebral disc degeneration.
Sano T; Akeda K; Yamada J; Takegami N; Sudo T; Sudo A
BMC Musculoskelet Disord; 2019 May; 20(1):225. PubMed ID: 31101043
[TBL] [Abstract][Full Text] [Related]
8. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
9. [Osteoprotegerin mRNA/receptor activator of NF-kappaB ligand mRNA expressions in bone tissues of glucocorticoid-induced osteonecrosis of the femoral head].
Wang J; Wang K; Shi Z; Zhang M
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Oct; 22(10):1161-4. PubMed ID: 18979868
[TBL] [Abstract][Full Text] [Related]
10. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
11. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
[TBL] [Abstract][Full Text] [Related]
12. Expression profile of osteoprotegerin, RANK and RANKL genes in the femoral head of patients with avascular necrosis.
Samara S; Dailiana Z; Chassanidis C; Koromila T; Papatheodorou L; Malizos KN; Kollia P
Exp Mol Pathol; 2014 Feb; 96(1):9-14. PubMed ID: 24200492
[TBL] [Abstract][Full Text] [Related]
13. RANK/RANKL/OPG system in the intervertebral disc.
Takegami N; Akeda K; Yamada J; Sano T; Murata K; Huang J; Masuda K; Sudo A
Arthritis Res Ther; 2017 Jun; 19(1):121. PubMed ID: 28576140
[TBL] [Abstract][Full Text] [Related]
14. Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease.
Vachliotis ID; Polyzos SA
Curr Obes Rep; 2023 Jun; 12(2):147-162. PubMed ID: 37208545
[TBL] [Abstract][Full Text] [Related]
15. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.
Vitovski S; Phillips JS; Sayers J; Croucher PI
J Biol Chem; 2007 Oct; 282(43):31601-9. PubMed ID: 17702740
[TBL] [Abstract][Full Text] [Related]
16. Zinc supplements and bone health: The role of the RANKL-RANK axis as a therapeutic target.
Amin N; Clark CCT; Taghizadeh M; Djafarnejad S
J Trace Elem Med Biol; 2020 Jan; 57():126417. PubMed ID: 31653549
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotective Effect of Cimiracemate in Glucocorticoid-Induced Osteoporosis by Osteoprotegerin/Receptor Activator of Nuclear Factor κ B/Receptor Activator of Nuclear Factor Kappa-Β Ligand Signaling.
Ding Z; Shi H; Yang W
Pharmacology; 2019; 103(3-4):163-172. PubMed ID: 30695776
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-34a alleviates steroid-induced avascular necrosis of femoral head by targeting Tgif2 through OPG/RANK/RANKL signaling pathway.
Peng WX; Ye C; Dong WT; Yang LL; Wang CQ; Wei ZA; Wu JH; Li Q; Deng J; Zhang J
Exp Biol Med (Maywood); 2017 Jun; 242(12):1234-1243. PubMed ID: 28454497
[TBL] [Abstract][Full Text] [Related]
19. Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats.
Lu J; Liu F; Liu D; Du H; Hao J; Yang X; Cui W
Exp Biol Med (Maywood); 2016 Jun; 241(11):1237-49. PubMed ID: 26908571
[TBL] [Abstract][Full Text] [Related]
20. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
